FH-EARLY is a multi-national initiative funded by the European Union, uniting 15 partners across Europe and beyond. Our shared goal is to co-develop and validate three core solutions to improve the early diagnosis, risk stratification, and co-management of FH:
We work hand-in-hand with patients living with FH, families, and clinicians to ensure our innovations are ethical, accessible, and impactful. Through workshops, interviews, and the Expert Patient Panel (EPP), we gather insights that shape the development of all three solutions.
FH-EARLY aims to revolutionise the diagnosis and management of FH through a multi-pronged approach that emphasizes innovation, patient engagement, and clinical integration. The project involves active co-creation with people living with FH, their families, and care teams to ensure that solutions are aligned with real-world needs. It leverages federated, multi-modal datasets derived from real-world data to deepen understanding and enable robust analysis.
Developing cutting-edge solutions including a novel chip array, signature biomarker assay, and AI-powered health profiling to advance early diagnosis and treatment.
Working hand-in-hand with people living with FH, families, and clinicians to ensure our tools are ethical, accessible, clinically relevant and meet real-world needs.
Leveraging federated, multi-modal real-world data and advanced analytics to deepen understanding and enable robust, personalised care.
FH-EARLY represents a fantastic oportunity to improve and expand early identification of individuals with familial hypercholesterolemia. It puts together all the stakeholders involved in FH, from the patient to the doctor, in order to improve the lives of people living with this disorder.
Prof. Fausto J. Pinto President, Cardiovascular Center of the University of Lisbon (CCUL), FH-EARLY Coordinator
FH-EARLY is a promise of breakthrough, where individuals and families with FH co-design and co-create innovative solutions with researchers and doctors, to detect risk early and to prevent the preventable heart disease.
Magdalena Daccord CEO, FH Europe Foundation
FH-EARLY is about redefining cardiovascular health by combining technological innovation with advanced social sciences and genuine patient involvement from the beginning. By listening to people’s preferences and attitudes from the start, we can build smarter, fairer, and more human technological solutions that truly fit their lives.
Dr Marius Geanta President and Co-Founder of Center for Innovation in MedicineProject Title:
New Strategies for the Early Diagnosis, Risk Stratification and Co-Management of Familial Hypercholesterolemia
Programme:
Horizon Europe – HORIZON-HLTH-2024-DISEASE-03
Coordinator:
Associação para Investigação e Desenvolvimento da Faculdade de Medicina (AIDFM - CCUL), Portugal
Milestones:
36 deliverables, 30 milestones; clinical studies and prototype testing begin mid-project
